Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by Enterobacteriaceae

In 2018, the Clinical and Laboratory Standards Institute (CLSI) revised ciprofloxacin (CIP)-susceptible breakpoint for Enterobacteriaceae from ≤1 μg/mL to ≤0.25 μg/mL, based on pharmacokinetic-pharmacodynamic (PK-PD) analysis. However, clinical data supporting the lowered CIP breakpoint are insuffic...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Ga Eun, Ko, Jae-Hoon, Cho, Sun Young, Huh, Hee Jae, Baek, Jin Yang, Ko, Kwan Soo, Kang, Cheol-In, Chung, Doo Ryeon, Peck, Kyong Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074352/
https://www.ncbi.nlm.nih.gov/pubmed/33924153
http://dx.doi.org/10.3390/antibiotics10040469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074352/
https://www.ncbi.nlm.nih.gov/pubmed/33924153
http://dx.doi.org/10.3390/antibiotics10040469

Ejemplares similares